Associations between lipid measures and metabolic syndrome, insulin resistance and adiponectin - Usefulness of lipid ratios in Korean men and women

Circulation Journal

Volumn 74, Issue 5, 2010, Pages 931-937

  Kimm, Heejin ^a   Lee, Sang Wha ^b   Lee, Hong Soo ^b   Shim, Kyung Won ^b   Cho, Choo Yon ^c   Yun, Ji Eun ^a   Jee, Sun Ha ^a  

^a Yonsei University   (South Korea)

^b Ewha Womans University School of Medicine   (South Korea)

^c Soonchunhyang University College of Medicine   (South Korea)

Author keywords

High density lipoprotein; Insulin resistance; Lipids; Metabolic syndrome; Triglycerides

Indexed keywords

ADIPONECTIN; CHOLESTEROL; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; LOW DENSITY LIPOPROTEIN CHOLESTEROL; TRIACYLGLYCEROL;

ADULT; ARTICLE; CHOLESTEROL BLOOD LEVEL; CONTROLLED STUDY; CROSS-SECTIONAL STUDY; FEMALE; HUMAN; INSULIN RESISTANCE; KOREA; MAJOR CLINICAL STUDY; MALE; METABOLIC SYNDROME X; TRIACYLGLYCEROL BLOOD LEVEL;

ADIPONECTIN; ADULT; ASIAN CONTINENTAL ANCESTRY GROUP; FEMALE; HUMANS; INSULIN RESISTANCE; LIPIDS; MALE; METABOLIC SYNDROME X; MIDDLE AGED; MODELS, BIOLOGICAL; REPUBLIC OF KOREA;

EID: 77951741261     PISSN: 13469843     EISSN: 13474820     Source Type: Journal    
DOI: 10.1253/circj.CJ-09-0571     Document Type: Article

References (29)

1. Reaven GM. Banting Lecture 1988: Role of insulin resistance in human disease. Diabetes 1988; 37: 1595-1607.
2. Reaven GM. Role of insulin resistance in human disease (Syndrome X): An expanded definition. Annu Rev Med 1993; 44: 121-131.
3. Isomaa B, Almgren P, Tuomi T, Forsen B, Lahti K, Nissen M, et al. Cardiovascular morbidity and mortality associated with the metabolic syndrome. Diabetes Care 2001; 24: 683-689.
4. Meigs JB. Epidemiology of the metabolic syndrome, 2002. J Manag Care 2002; 8: S283-S292; quiz S293-S296.
5. Kajimoto K, Kasai T, Miyauchi K, Hirose H, Yanagisawa N, Yamamoto T, et al. Metabolic syndrome predicts 10-year mortality in non-diabetic patients following coronary artery bypass surgery. Circ J 2008; 72: 1481-1486.
6. Lakka HM, Laaksonen DE, Lakka TA, Niskanen LK, Kumpusalo E, Tuomilehto J, et al. The metabolic syndrome and total and cardiovascular disease mortality in middle-aged men. JAMA 2002; 288: 2709-2716.
7. Saito I, Iso H, Kokubo Y, Inoue M, Tsugane S. Metabolic syndrome and all-cause and cardiovascular disease mortality: Japan Public Health Center-based Prospective (JPHC) Study. Circ J 2009; 73: 878-884.
8. Tseng CH, Chong CK, Tseng CP, Shau WY, Tai TY. Hypertension is the most important component of metabolic syndrome in the association with ischemic heart disease in Taiwanese type 2 diabetic patients. Circ J 2008; 72: 1419-1424.
9. Kahn R, Buse J, Ferrannini E, Stern M. The metabolic syndrome: Time for a critical appraisal: Joint statement from the American Diabetes Association and the European Association for the Study of Diabetes. Diabetologia 2005; 48: 1684-1699.
10. Shah PK, Kaul S, Nilsson J, Cercek B. Exploiting the vascular protective effects of high-density lipoprotein and its apolipoproteins: An idea whose time for testing is coming. Part I. Circulation 2001; 6: 2376-2383.
11. Egger M, Smith GD, Pfluger D, Altpeter E, Elwood PC. Triglyceride as a risk factor for ischaemic heart disease in British men: Effect of adjusting for measurement error. Atherosclerosis 1999; 143: 275-284.
12. Sharrett AR, Ballantyne CM, Coady SA, Heiss G, Sorlie PD, Catellier D, et al. Coronary heart disease prediction from lipoprotein cholesterol levels, triglycerides, lipoprotein(a), apolipoproteins A-I and B, and HDL density subfractions: The Atherosclerosis Risk in Communities (ARIC) Study. Circulation 2001; 104: 1108-1113.
13. Executive Summary of The Third Report of The National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III). JAMA 2001; 285: 2486-2497.
14. McLaughlin T, Abbasi F, Cheal K, Chu J, Lamendola C, Reaven G. Use of metabolic markers to identify overweight individuals who are insulin resistant. Ann Intern Med 2003; 139: 802-809.
15. McLaughlin T, Reaven G, Abbasi F, Lamendola C, Saad M, Waters D, et al. Is there a simple way to identify insulin-resistant individuals at increased risk of cardiovascular disease? Am J Cardiol 2005; 96: 399-404.
16. Hannon TS, Bacha F, Lee SJ, Janosky J, Arslanian SA. Use of markers of dyslipidemia to identify overweight youth with insulin resistance. Pediatr Diabetes 2006; 7: 260-266.
17. Ridker PM, Rifai N, Cook NR, Bradwin G, Buring JE. Non-HDL cholesterol, apolipoproteins A-I and B100, standard lipid measures, lipid ratios, and CRP as risk factors for cardiovascular disease in women. JAMA 2005; 294: 326-333.
18. Chien KL, Hsu HC, Su TC, Chen MF, Lee YT, Hu FB. Apolipoprotein B and non-high density lipoprotein cholesterol and the risk of coronary heart disease in Chinese. J Lipid Res 2007; 48: 2499-2505.
19. Ingelsson E, Schaefer EJ, Contois JH, McNamara JR, Sullivan L, Keyes MJ, et al. Clinical utility of different lipid measures for prediction of coronary heart disease in men and women. JAMA 2007; 298: 776-785.
20. Ryo M, Nakamura T, Kihara S, Kumada M, Shibazaki S, Takahashi M, et al. Adiponectin as a biomarker of the metabolic syndrome. Circ J 2004; 68: 975-981.
21. World Health Organization Western Pacific Region/International Association for the Study of Obesity (IASO)/International Obesity Taskforce (IOTF). The Asia-Pacific perspective: Redefining obesity and its treatment. Melbourne: Health Communications Australia, 2000; 31-33.
22. Matthews DR, Hosker JP, Rudenski AS, Naylor BA, Treacher DF, Turner RC. Homeostasis model assessment: Insulin resistance and beta-cell function from fasting plasma glucose and insulin concentrations in man. Diabetologia 1985; 28: 412-419.
23. Yoon SJ, Lee HS, Lee SW, Yun JE, Kim SY, Cho ER, et al. The association between adiponectin and diabetes in the Korean population. Metabolism 2008; 57: 853-857.
24. Higashiyama A, Okamura T, Ono Y, Watanabe M, Kokubo Y, Okayama A. Risk of smoking and metabolic syndrome for incidence of cardiovascular disease. Circ J 2009; 73: 2258-2263.
25. Li C, Ford ES, Meng YX, Mokdad AH, Reaven GM. Does the association of the triglyceride to high-density lipoprotein cholesterol ratio with fasting serum insulin differ by race/ethnicity? Cardiovasc Diabetol 2008; 7: 4.
26. Kannel WB, Vasan RS, Keyes MJ, Sullivan LM, Robins SJ. Usefulness of the triglyceride-high-density lipoprotein versus the cholesterol-high-density lipoprotein ratio for predicting insulin resistance and cardiometabolic risk (from the Framingham Offspring Cohort). Am J Cardiol 2008; 101: 497-501.
27. Walldius G, Jungner I, Holme I, Aastveit AH, Kolar W, Steiner E. High apolipoprotein B, low apolipoprotein A-I, and improvement in the prediction of fatal myocardial infarction (AMORIS study): A prospective study. Lancet 2001; 358: 2026-2033.
28. Lee KH, Sohn JC, Kim BT, Choi BH, Jung SH, Cha CK, et al. NonHDL cholesterol as a predictive factor for metabolic syndrome in Korean women. Korean J Obes 2007; 16: 102-110 (in Korean).
29. Sumner AE, Finley KB, Genovese DJ, Criqui MH, Boston RC. Fasting triglyceride and the triglyceride-HDL cholesterol ratio are not markers of insulin resistance in African Americans. Arch Intern Med 2005; 165: 1395-1400.